IL25 and obesity due to melanocortin 4 receptor deficiency: Therefore, the potential application of IL-17E in treating kidney diseases, particularly in mitigating kidney injury caused by IRI, drug toxicity, or obesity, warrants further clinical research and exploration (Fig. 3E and Fig. S7).